News

Diet, exercise in prediabetes may prevent long-term progression and mortality


 

FROM THE LANCET DIABETES & ENDOCRINOLOGY

A 6-year program of diet, exercise, or both helped delay the onset of diabetes in adults, and had significant mortality benefits for women 23 years later, researchers reported online in the Lancet Diabetes & Endocrinology.

The Da Qing Diabetes Prevention Study "is the first to show that lifestyle intervention in people with impaired glucose tolerance can both reduce the incidence of diabetes and decrease mortality," said Dr. Guangwei Li at the China-Japan Friendship Hospital in Beijing and his associates.

©Pavel Losevsky/iStockphoto.com

Altering dietary and exercise habits may be the best option for patients who wish to delay the onset of diabetes.

They added that the results "provide yet further justification to implement lifestyle interventions for people with impaired glucose tolerance.".

The investigators randomized 577 Chinese adults with impaired glucose tolerance to a control group or to a 6-year intervention program consisting of diet, exercise, or both. The exercise program focused on increasing leisure physical activity, while the diet program promoted weight loss when indicated and reduction of carbohydrate and alcohol intake.

At 23-year follow-up, the intervention group had significantly lower rates of cardiovascular mortality, at 11.9% vs. 19.6%, for a relative risk reduction of 41%; all-cause mortality, at 28.1% vs. 38.4%, for a RRR of 29%; and diabetes, at 72.6% vs. 89.9%, yielding a RRR of 45% (Lancet Diabetes Endocrinol. 2014 [doi: 10.1016/S2213-8587(14)70057-9]).

But the mortality benefit was significant only in women, in whom the risk reductions were 54% and 72% for cardiovascular and all-cause death, respectively, compared with just 3% and 9% in men. The researchers said they could not determine why the mortality benefit was seen primarily in women. Controlling for a higher smoking rate in men did not account for the difference, they said.

The U.S. Centers for Disease Control and Prevention, the World Health Organization, the China-Japan Friendship Hospital, and the Da Qing First Hospital funded the study. The investigators reported that they had no competing interests.

Recommended Reading

No improvements in left ventricular function with metformin after myocardial infarction
MDedge Cardiology
'Revolutionary' LDL lowering shown in evolocumab phase III trials
MDedge Cardiology
'Favorable signal' for secondary coronary prevention in STABILITY
MDedge Cardiology
VIDEO: Novel drug misses mark for MI prevention, but shows promise
MDedge Cardiology
Evolocumab betters ezetimibe for lowering LDL in statin-intolerant patients
MDedge Cardiology
Bariatric surgery’s benefit persists in type 2 diabetes
MDedge Cardiology
One in four patients with hypertension nonadherent to therapy
MDedge Cardiology
VIDEO: PCSK9 inhibitors placed in perspective
MDedge Cardiology
ACC/AHA cardiovascular risk equations get a thumbs-up
MDedge Cardiology
Diabetes prevalence increases, but so does diabetes control
MDedge Cardiology